Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 6, keine Gesamtzahl für „Remsima“
Suchtreffer
Begriffe & Kennungen
Remsima · 4.8 · Immunogenicity
Eintrag öffnenRemsima · 4.8 · Immunogenicity
Eintrag öffnenRemsima · 4.8 · Immunogenicity
Eintrag öffnenRemsima · 4.8 · Immunogenicity Antibodies to infliximab developed in 38% of patients receiving 3 mg/kg compared with 12% of pa
Eintrag öffnenRemsima · 4.8 · Immunogenicity Antibodies to infliximab developed in 38% of patients receiving 3 mg/kg compared with 12% of pa
Eintrag öffnenRemsima · 4.8 · Immunogenicity Antibodies to infliximab were detected in 3 (2.9%) paediatric patients.
Eintrag öffnenRemsima · 4.8 · Immunogenicity Antibodies to infliximab were detected in 3 (2.9%) paediatric patients.
Eintrag öffnenRemsima · 4.8 · Immunogenicity Antibodies to infliximab were detected in 4 (7.7%) patients through week 54.
Eintrag öffnenRemsima · 4.8 · Immunogenicity Antibodies to infliximab were detected in 4 (7.7%) patients through week 54.
Eintrag öffnenRemsima · 4.8 · In Crohn's disease and ulcerative colitis patients on maintenance treatment, the incidence of anti-infliximab
Eintrag öffnenRemsima · 4.8 · In a 1-year clinical study with repeated infusions in patients with Crohn's disease (ACCENT I study), the inci
Eintrag öffnenRemsima · 4.8 · In a 1-year clinical study with repeated infusions in patients with Crohn's disease (ACCENT I study), the inci
Eintrag öffnenRemsima · 4.8 · In a Phase II study aimed at evaluating infliximab in CHF, higher incidence of mortality due to worsening of h
Eintrag öffnenRemsima · 4.8 · In a Phase II study aimed at evaluating infliximab in CHF, higher incidence of mortality due to worsening of h
Eintrag öffnenRemsima · 4.8 · In a Phase II study aimed at evaluating infliximab in CHF, higher incidence of mortality due to worsening of h
Eintrag öffnenRemsima · 4.8 · In a clinical study of patients with Crohn’s disease (SONIC), infusion-related reactions occurred in 16.6% (27
Eintrag öffnenRemsima · 4.8 · In a clinical study of patients with Crohn’s disease (SONIC), infusion-related reactions occurred in 16.6% (27
Eintrag öffnenRemsima · 4.8 · In a clinical study of patients with rheumatoid arthritis (ASPIRE), infusions were to be administered over 2 h
Eintrag öffnenRemsima · 4.8 · In a clinical study of patients with rheumatoid arthritis (ASPIRE), infusions were to be administered over 2 h
Eintrag öffnenRemsima · 4.8 · In addition, post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with
Eintrag öffnen